CRISPR Therapeutics(NASDAQ) CRSP

CRISPR Therapeutics makes medicines that fix broken genes to treat life-changing diseases. Its technology acts like a pair of molecular scissors that can precisely edit DNA. These treatments help people suffering from serious blood disorders and cancer.

The Genetic Toolkit

• CASGEVY: Gene-edited cell therapy used to treat sickle cell disease and beta thalassemia; developed with partner Vertex Pharmaceuticals.
• Hematology Pipeline: Research programs focused on blood disorders; uses patient stem cells to produce healthy fetal hemoglobin.
• Cancer Immunotherapy: Investigational treatments that edit immune cells to target and kill tumors; includes candidates like zugocabtagene geleucel.
• Regenerative Medicine: Development of insulin-producing cells for diabetes; aims to replace injections with engineered cell transplants.
• In Vivo Programs: Therapies delivered directly into the body; targets diseases in the liver, lungs, and central nervous system.

New Paths for Growth

• Secured the first-ever global regulatory approval for a CRISPR-based medicine, CASGEVY, in 2023 with partner Vertex Pharmaceuticals.
• Entered a collaboration with Sirius Therapeutics in May 2025 to develop RNA-based therapies for heart and blood diseases.
• Gained full control of diabetes research assets in February 2024 after ViaCyte opted out of a joint development agreement.
• Formed a clinical supply agreement with Eli Lilly to test cancer treatments alongside existing oncology drugs.

How the Firm Competes

The company operates its own manufacturing facility in Massachusetts to control the production of specialized cell therapies. It maintains a large portfolio of gene-editing techniques that range from editing cells outside the body to direct treatments inside the body.

Key Financial Facts

• Revenue grew to $1.5 million in Q1 2026, up 68.6% from $865,000 in Q1 2025.
• Net loss narrowed to $122.9 million in Q1 2026, representing a 9.6% improvement year-over-year.
• Operating cash flow reached negative $108.9 million in Q1 2026, a 101.9% decrease from the previous year.
• Cash and marketable securities totaled $2.4 billion as of March 2026, supported by a $600 million debt offering.

Bottom Line

CRISPR Therapeutics has transitioned from a research platform into a commercial-stage company with the world's first approved gene-editing drug. Its diverse pipeline and high cash reserves support long-term development across multiple disease areas.